Financial Performance - The company's operating revenue for Q3 2025 was ¥31,846,328.33, a decrease of 11.76% compared to the same period last year[5]. - Net profit attributable to shareholders reached ¥8,716,747.48, reflecting a significant increase of 48,724.30% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥7,053,860.31, up 444.37% from the previous year[5]. - The company reported a basic earnings per share of ¥0.0264, an increase of 26,500.00% year-on-year[5]. - The weighted average return on equity was 3.66%, up from 2.18% in the same period last year[5]. - Total operating revenue for the current period is 83,438,454.98, down from 92,417,062.87 in the previous period, representing a decrease of approximately 11.4%[20]. - The net profit for the current period is -3,149,584.02, an improvement from -8,885,815.36 in the previous period, reflecting a reduction in losses[21]. - The basic and diluted earnings per share for the current period are 0.0159, compared to -0.0255 in the previous period, showing a positive turnaround[22]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥841,955,975.52, representing a growth of 38.44% compared to the end of the previous year[5]. - Total assets amount to 841,955,975.52, up from 608,169,817.97 in the previous period, indicating a growth of about 38.3%[19]. - Total liabilities are 479,299,987.90, compared to 326,171,710.73 in the previous period, representing an increase of approximately 46.8%[19]. - The company's equity attributable to shareholders is 242,327,514.63, up from 237,095,180.02 in the previous period, reflecting a slight increase of about 2.0%[19]. Investments and Acquisitions - The company experienced a 16425.49% increase in trading financial assets, totaling ¥100,456,626.00 due to reclassification of other non-current financial assets[10]. - Long-term borrowings increased by 738.72% to ¥75,485,000.00, attributed to the addition of a new subsidiary[11]. - The company reported a 154.14% increase in investment income, totaling ¥5,310,324.47, primarily from trust financial products[11]. - The company initiated the sale of a 52% stake in Nanhua Peace Hospital Management (Hunan) Co., Ltd. at a base price of 19.9919 million RMB, with the transaction completed on October 21, 2025[14]. - The company acquired a 43.05% stake in Loudi Jinhong New Materials Co., Ltd. for 48.6249 million RMB and increased its investment by 30 million RMB, achieving a controlling stake of 55%[15]. - The company is planning to acquire a 51% stake in Hunan Huize Biological Pharmaceutical Technology Co., Ltd., with ongoing due diligence and negotiations[16]. Cash Flow and Expenditures - Cash flow from operating activities increased to 129,067,161.46 from 121,599,540.26 in the previous period, marking an increase of approximately 6.1%[24]. - Total cash inflow from investment activities was $110,346,204.21, down from $223,029,733.17, indicating a decrease in investment returns[26]. - Cash outflow from investment activities totaled $167,039,408.23, compared to $328,548,828.94 previously, showing a reduction in investment expenditures[26]. - Net cash flow from financing activities was -$5,344,267.76, a decrease from -$180,471,647.76, suggesting improved financing conditions[26]. - The ending cash and cash equivalents balance was $162,620,548.64, down from $214,707,973.70, indicating a decline in liquidity[26]. - Cash received from the recovery of investments was $105,000,000.00, down from $218,149,937.31, reflecting a decline in investment recoveries[25]. - Cash paid for the acquisition of fixed assets was $813,823.20, significantly lower than $16,052,536.23 in the previous period, indicating reduced capital expenditures[26]. Operational Strategy - The company has implemented multiple asset transactions and business expansion initiatives to optimize its business structure and mitigate operational risks[14]. - The company’s financial performance and strategic moves indicate a focus on enhancing core business competitiveness and exploring new profit growth points[14]. - Research and development expenses for the current period are 6,236,518.78, down from 7,034,234.69 in the previous period, indicating a decrease of approximately 11.3%[20]. Future Outlook - The company reported a total profit and net profit for 2024 expected to be negative, with operating revenue projected to be below 300 million RMB, raising investment risk concerns[14]. - The company did not undergo an audit for the third quarter financial report, which may affect investor confidence[27]. - The company plans to implement new accounting standards starting in 2025, which may impact future financial reporting[28].

证券代码：000504 证券简称：*ST 生物 公告编号：2025-063 南华生物医药股份有限公司 关于挂牌出售控股子公司股权的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 特别提示： 南华生物医药股份有限公司（以下简称"公司"）于2025年6月18日召开了 第十一届董事会第二十八次会议，审议通过了《关于授权经营层挂牌出售子公司 股权的议案》，拟通过湖南省联合产权交易所有限公司（以下简称"湖南联交所"） 公开挂牌出售持有的南华和平医院管理（湖南）有限公司（以下简称"南华和平" 或"标的公司"）全部股权；并分别于2025年8月21日、2025年9月20日披露了《关 于挂牌出售控股子公司股权的进展公告》。相关详情请见公司于2025年6月19日、 2025年8月21日和2025年9月20日在巨潮资讯网披露的公告（公告编号：2025-031、 2025-049、2025-058）。 截至本公告披露日，本次挂牌出售程序已结束。根据湖南联交所 2025 年 10 月 20 日出具的《网络竞价结果通知书（一次报价）》，确认本次南华和平 52% 股权的受让方为中关 ...

Market Overview - On October 23, the medical services sector rose by 0.19% compared to the previous trading day, with Bid Pharma leading the gains [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] Top Gainers in Medical Services - Bid Pharma (688073) closed at 71.15, up 5.27% with a trading volume of 11,500 lots and a transaction value of 799.13 million [1] - ST Zhongzhu (600568) closed at 2.02, up 5.21% with a trading volume of 400,000 lots and a transaction value of 794.03 million [1] - Other notable gainers include *ST Biology (000504) at 9.50, up 2.48%, and Kanglong Chemical (300759) at 31.44, up 1.55% [1] Top Losers in Medical Services - Haitai Bio (300683) closed at 32.06, down 7.15% with a trading volume of 136,900 lots and a transaction value of 440 million [2] - Innovative Medical (002173) closed at 22.32, down 5.10% with a trading volume of 639,200 lots and a transaction value of 143.2 million [2] - Other significant decliners include Chengda Pharmaceutical (301201) at 32.70, down 3.77%, and Heyuan Bio (688238) at 7.49, down 2.60% [2] Capital Flow Analysis - On the same day, the medical services sector experienced a net outflow of 637 million from institutional investors, while retail investors saw a net inflow of 723 million [2][3] - The overall capital flow indicates that while institutional investors were pulling back, retail investors were actively buying into the sector [2][3] Individual Stock Capital Flow - For Aier Eye Hospital (300015), there was a net outflow of 20.59 million from institutional investors, while retail investors contributed a net inflow of 231,940 [3] - Kanglong Chemical (300759) saw a net inflow of 17.04 million from institutional investors, but a net outflow of 2.59 million from retail investors [3] - Bid Pharma (688073) had a net inflow of 1.08 million from institutional investors, while retail investors contributed a net inflow of 504,580 [3]

南华生物医药股份有限公司 关于控股孙公司诉讼事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 一、本次诉讼事项的基本情况 南华生物医药股份有限公司（以下简称"公司"）控股孙公司城光（湖南） 节能环保服务股份有限公司（以下简称"城光公司"或"城光节能"）就其与江 苏四方清洁能源装备制造有限公司(原名江苏四方锅炉有限公司）（以下简称"四 方公司"）买卖合同纠纷一案向长沙市芙蓉区人民法院提起诉讼，请求判令四方 公司返还城光公司合同价款人民币 1,500 万元；判令四方公司赔偿城光公司资金 占用费(按一年期 LPR 加 50%的利息标准,1,300 万元从 2020 年 9 月 10 日暂计算 至 2024 年 6 月 30 日,200 万元从 2021 年 2 月 10 日暂计算至 2024 年 6 月 30 日, 后续 1,500 万元计算至全部款项付清之日止)，并由四方公司承担本案案件受理 费、保全费、保全保险费等全部诉讼费用；2025 年 1 月 10 日，公司收到城光节 能转来的《湖南省长沙市芙蓉区人民法院民事判决书》[（2024）湘 010 ...

一、本次交易概述 南华生物医药股份有限公司（以下简称"公司"或"南华生物"）于2025年 8月12日披露了《关于筹划重大资产重组暨签署股权收购意向协议的提示性公告》 （公告编号：2025-047），并于2025年9月11日披露了《关于筹划重大资产重组 的进展公告》。公司拟收购程泽能、易木林、长沙君合致远企业管理咨询合伙企 业（有限合伙）、长沙市履方医药信息咨询合伙企业（有限合伙）合计持有的湖 南慧泽生物医药科技有限公司（以下简称"慧泽医药"或"标的公司"）51%股 权。本次交易完成后，慧泽医药将成为南华生物控股子公司并纳入合并报表范围。 根据初步测算，本次交易预计构成《上市公司重大资产重组管理办法》规定 的重大资产重组情形。本次交易不构成关联交易，不涉及公司发行股份，亦不会 导致公司控制权发生变更。 二、交易进展情况 证券代码：000504 证券简称：*ST 生物 公告编号：2025-061 南华生物医药股份有限公司 关于筹划重大资产重组的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 截至本公告披露日，本次交易尚处于筹划阶段，相关尽职调查、审计、 ...

2025年8月12日，南华生物医药披露筹划重大资产重组，拟收购程泽能等合计持有的湖南慧泽生物医药 科技有限公司51%股权，交易完成后慧泽医药将成其控股子公司。初步测算，本次交易预计构成重大资 产重组，不构成关联交易，不涉及发行股份及控制权变更。截至10月10日，公司已委托中介开展尽职调 查、审计及评估工作，交易相关方就核心条款密切沟通，但未签正式协议。本次交易尚处筹划阶段，后 续需经内部审批，最终能否达成存在不确定性，公司提醒投资者注意风险。 ...

证券代码：000504 证券简称：*ST生物 公告编号：2025-060 南华生物医药股份有限公司 关于收购娄底金弘新材料有限公司股权暨 完成工商变更的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 重要提示： 1、南华生物医药股份有限公司（以下简称"公司"或"南华生物"）以 4,862.49 万元自有资金收购湖南金弘再生资源集团有限公司持有的娄底金弘新 材料有限公司（以下简称"标的公司"）43.05%股权；公司同时对标的公司增资 3,000 万元，其中 2,615.75 万元计入标的公司注册资本，其余金额计入标的公 司资本公积。本次股权转让及增资完成后，公司对标的公司的持股比例为 55%， 取得对标的公司的控制权，标的公司将纳入公司合并报表范围。 2、本次交易分别已经公司第十二届董事会第三次会议和 2025 年第三次临 时股东会审议通过。标的公司工商变更登记已完成，后续仍存在款项支付、承诺 履行等方面的不确定性，敬请投资者注意投资风险。相关具体详情请见公司于 2025 年 9 月 6 日及 2025 年 9 月 23 日在巨潮资讯网披露的公告（公 ...

Meeting Overview - The shareholder meeting was held on September 22, 2025, with both on-site and online voting options available [3][4] - The meeting was convened by the company's 12th Board of Directors and presided over by Chairman Yang Yun [4] Attendance - A total of 366 shareholders attended the meeting, representing 175,062,605 shares, which accounts for 53.0456% of the company's voting shares [5][7] - Among these, 364 were small shareholders, representing 41,311,753 shares, or 12.5178% of the voting shares [8][10] Proposal Voting Results - The proposal to acquire equity in Loudi Jinhong New Materials Co., Ltd. through cash and capital increase was approved, with 154,186,756 shares in favor, representing 88.0752% of the valid votes [13] - Small shareholders voted 20,435,904 shares in favor, which is 49.4675% of their valid votes, while 50.5322% opposed the proposal [14] Legal Opinion - The legal opinion provided by Hunan Xiangjun Luhe Law Firm confirmed that the meeting's notice, convening, and voting procedures complied with relevant laws and regulations [15]

湖南湘军麓和律师事务所 关于南华生物医药股份有限公司 2025 年第三次临时股东会的 法律意见书 湖南湘军麓和律师事务所 HUNAN XIANGJUNLUHE LAW FIRM 二○二五年九月 湖南湘军麓和律师事务所 关于南华生物医药股份有限公司 2025 年第三次临时股东会的法律意见书 致：南华生物医药股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）和中国证券监督管理委员会发布的 《上市公司股东会规则》（以下简称"《股东会规则》"）、《深圳证券交易所 上市公司股东会网络投票实施细则》（以下简称"《网络投票实施细则》"）等 有关规定，湖南湘军麓和律师事务所（以下简称"本所"）接受南华生物医药股 份有限公司（以下简称"公司"）的聘请，指派陈琳律师、向思律师（以下简称 "本所律师"）出席并见证了公司于 2025 年 9 月 22 日（星期一）15:00 在长沙 高新开发区岳麓西大道1698号麓谷科技创新创业园B1栋三层会议室召开的公司 2025 年第三次临时股东会（以下简称"本次会议"），并依据有关法律、法规、 规范性文件的规定以及《南华生 ...

1.会议召开时间： （1）现场会议召开时间：2025年9月22日15:00 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 特别提示： 1.本次股东会未出现否决提案的情形； 2.本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 证券代码：000504 证券简称：*ST生物 公告编号：2025-059 南华生物医药股份有限公司 2025 年第三次临时股东会决议公告 1.股东出席的总体情况： 6.会议召开的合法合规性：本次股东会会议召开符合《公司法》《证券法》 《上市公司股东会规则》等法律、法规和《公司章程》的规定。 （2）网络投票时间：2025年9月22日（星期一）。其中：通过深圳证券交易 所交易系统进行网络投票的具体时间为2025年9月22日9:15-9:25，9:30－11:30， 13:00-15:00；通过互联网投票系统进行网络投票的时间为2025年9月22日 9:15-15:00。 2.会议召开的地点：长沙高新开发区岳麓西大道1698号麓谷科技创新创业园 B1栋三层会议室 3.会议召开的方式：现场表决与网络投票 ...